The Latest Breaking News from diabetes

Danish pharmaceutical company Novo Nordisk, maker of weight-loss drug Wegovy, said Wednesday it would cut 9,000 jobs, 5,000 of them in Denmark, in order to strengthen the company’s focus on growth opportunities in obesity and diabetes medications

People with diabetes were most likely to be diagnosed in high-income North America, and most likely to be treated in high-income Asia Pacific.

Among western European countries, only Switzerland and France had lower diagnosis rates than the UK

Some 74.2% of people with the condition were estimated to have been diagnosed in the UK.

Ozempic and Zepbound have morphed from diabetes treatment into a cultural phenomenon, helping Novo Nordisk A/S (NYSE:NVO) and Eli Lilly And Co (NYSE:LLY) achieve a combined market cap topping $900 billion. Celebrities flaunt it, Silicon Valley elites swear by it, and analysts predict the GLP-1 market could surpass $150 billion…

The typical risk factors for major cardiovascular events include high blood pressure, high cholesterol, diabetes, or a history of smoking

GLP-1 drugs were initially developed for diabetes, but have become wildly popular weight-loss drugs too

IN FULL

The World Health Organization recommended a range of blockbuster weight-loss drugs to treat diabetes and obesity globally for the first time on Friday, calling for cheap generic versions to be made available for people in developing countries.